Quality of Life After Glaucoma Surgery: Evaluating the Patient Perspective Across Surgical Options
G-SCOPE
2 other identifiers
observational
132
1 country
1
Brief Summary
Glaucoma surgery currently relies on a wide therapeutic arsenal, ranging from conventional filtering surgeries to minimally invasive glaucoma surgery (MIGS). These techniques offer distinct efficacy and safety profiles, allowing tailored management across a broad spectrum of patients. Traditionally, surgical success has been evaluated using objective clinical outcomes, such as intraocular pressure (IOP) reduction and decreased reliance on topical treatments. However, the shift toward patient-centered medicine now requires consideration of the patient's perspective, including their subjective experience and the impact of treatment on quality of life. In this context, quality-of-life assessment has become a key component, promoting therapeutic alliance and patient adherence to care pathways. Despite its importance, few studies have evaluated and compared quality of life after glaucoma surgery using comparable surgical techniques. Furthermore, to our knowledge, no study has specifically assessed the independent effect of postoperative follow-up on quality of life after filtering surgery with a bleb. Given that postoperative management can be prolonged and demanding, it may significantly influence patients' perceptions of surgical outcomes and overall well-being. This study aims to address these gaps by providing a more comprehensive evaluation of the impact of glaucoma surgery beyond traditional clinical outcomes. It may represent a first step toward the development of a more appropriate assessment tool that incorporates the realities of postoperative follow-up and the specific experiences of patients undergoing filtering surgery. The study is based on the following hypotheses: filtering glaucoma surgery preserves patients' quality of life, with a stable NEI VFQ-25 score at six months postoperatively; postoperative quality of life may be influenced by the patient's postoperative care pathway; and quality-of-life scores remain correlated with objective clinical parameters, including intraocular pressure, visual acuity, medical treatment burden, and visual field damage.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Feb 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 11, 2025
CompletedFirst Posted
Study publicly available on registry
December 24, 2025
CompletedStudy Start
First participant enrolled
February 23, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 1, 2027
March 16, 2026
February 1, 2026
1.4 years
December 11, 2025
March 12, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Quality of life score from the NEI-VFQ-25 (National Eye Institute Visual Function Questionnaire-25).
To evaluate, in adult patients undergoing glaucoma surgery, the change in NEI-VFQ 25 quality of life score between the pre-operative period and 6ᵉ months post-operatively, regardless of the surgical technique used.
Pre-operative period and 6 months after intervention
Secondary Outcomes (5)
Comparison of NEI-VFQ-25 scores between surgical techniques
6 months postoperatively (M6)
Correlation between NEI-VFQ-25 score and postoperative clinical parameters
Postoperative visits at Month 3 (M3)
Correlation between NEI-VFQ-25 score and postoperative clinical parameters
Postoperative visits at Month 6 (M6)
Impact of postoperative follow-up on NEI-VFQ-25 quality-of-life scores at 3 months
Prospective collection of postoperative follow-up data through Month 3 (M3)
Impact of postoperative follow-up on NEI-VFQ-25 quality-of-life scores at 6 months
Prospective collection of postoperative follow-up data through Month 6 (M6)
Study Arms (1)
Adult with open-angle/angle-closure or exfoliative or pigmentary glaucoma and a surgical indication
Adult patient with different stage of glaucoma and a surgical indication for sclerectomy + Mitomycin, PRESERFLO + Mitomycin, or trabeculectomy + Mitomycin. .
Interventions
The NEI-VFQ-25 questionnaire, translated into French and validated by the French National Authority for Health (HAS), is used to assess quality of life related to visual function. This questionnaire includes 25 items divided into 11 subdomains assessing vision-related functioning and 1 subdomain assessing general health status (see appendix for the detailed list). The composite score ranges from 0 to 100, with lower scores indicating a poorer perceived level of health and visual functioning.
Eligibility Criteria
Glaucoma patients aged ≥ 18 years, operated on using one of the following 3 types of surgery: Trabeculectomy , Deep non-perforating sclerectomy or Preserflo
You may qualify if:
- Patient aged ≥ 18 years with an indication for glaucoma surgical treatment
- Eligible surgical procedures: Preserflo™ MicroShunt with mitomycin C, Trabeculectomy with mitomycin C or non-penetrating deep sclerectomy with mitomycin C
- Unilateral or bilateral glaucoma, open-angle or angle-closure, at early, moderate, or advanced stages
- Pseudoxexfoliative or pigmentary glaucoma
- Secondary glaucoma, including: uveitic glaucoma, Steroid-induced glaucoma, traumatic glaucoma
- Written informed consent obtained prior to study participation
You may not qualify if:
- Congenital glaucoma
- Refractory glaucoma with a history of multiple previous surgeries
- Severe visual co-morbidities (age-related macular degeneration, severe diabetic retinopathy, retinal degeneration, or similar conditions)
- Expected difficulty with follow-up including poor anticipated compliance, planned travel or prolonged absence during the follow-up period
- Illiteracy, inability to speak French or impaired cognitive capacity preventing adequate understanding of the study
- Patients with a significant pre-existing impairment in quality of life attributable to a progressive physical illness or a neuropsychiatric disorder.
- Patients under curatorship or guardianship
- Pregnant women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Service d'Ophtalmologie, Hôpital de La Croix Rousse, Hospices Civils de Lyon
Lyon, 69317, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 11, 2025
First Posted
December 24, 2025
Study Start
February 23, 2026
Primary Completion (Estimated)
August 1, 2027
Study Completion (Estimated)
August 1, 2027
Last Updated
March 16, 2026
Record last verified: 2026-02
Data Sharing
- IPD Sharing
- Will not share